Target intelligence / Profile preview

V-set immunoregulatory receptor (VISTA) (VISTA)

Target
VISTA
Molecular classification
Receptor, Immune checkpoint, B7 family protein, Type I transmembrane protein
01

Overview

V-set immunoregulatory receptor (VISTA) is a type I transmembrane protein and a member of the B7 family of immune checkpoint molecules that plays a critical role in maintaining peripheral tolerance (UniProt Q9H7M9). It is primarily expressed on myeloid cells, such as macrophages and dendritic cells, and is also found on T-lymphocytes, where it functions as a potent negative regulator of T-cell activation and cytokine production (Wang et al., 2011, PubMed: 21383057). In the tumor microenvironment, VISTA is often upregulated, contributing to immune evasion by suppressing anti-tumor T-cell responses and promoting the activity of myeloid-derived suppressor cells (Lines et al., 2014, PubMed: 24691993). Unlike other checkpoints like PD-1, VISTA's expression is frequently maintained or increased following treatment with other immunotherapies, making it a significant target for overcoming resistance in various cancers (Nowak et al., 2017, PubMed: 28923825). Therapeutic strategies currently focus on monoclonal antibodies designed to block VISTA's inhibitory signaling to enhance immune-mediated tumor clearance (ClinicalTrials.gov NCT02671955). Additionally, VISTA agonists are being explored for the treatment of autoimmune and inflammatory diseases to restore immune tolerance (ElTanbouly et al., 2020, PubMed: 32051256). A unique feature of VISTA is its pH-sensitive binding, which is being leveraged in drug design to target the acidic tumor microenvironment specifically (Johnston et al., 2019, PubMed: 31645450).

Other names
V-domain Ig suppressor of T-cell activationB7-H5GI24Dies1SISP1PD-1HVSIRPlatelet receptor Gi24
02

Mechanism of action

Immune checkpoint inhibition (antagonism) to enhance T-cell activity against tumors; Immune checkpoint activation (agonism) to suppress overactive immune responses in autoimmunity.

03

Biological functions

Immune responseNegative regulation of T-cell activationMyeloid cell regulationCytokine production regulationCell adhesion
04

Disease associations

CancerAutoimmune diseaseInflammationSystemic lupus erythematosus
05

Safety considerations

Cytokine release syndrome (CRS)Dose-limiting neutropeniaPotential for systemic inflammation or autoimmunityHigh target-mediated drug disposition (TMDD) due to broad expression
06

Interacting drugs

CI-8993

5 more in the full profile.

07

Biomarkers

VISTA protein expression (IHC)Myeloid-derived suppressor cell (MDSC) levelsT-cell infiltrationpH-dependent binding affinity

Beyond the preview

Go deeper on V-set immunoregulatory receptor (VISTA) (VISTA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-set immunoregulatory receptor (VISTA) (VISTA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call